Lucerastat

Research use only, not for human use.

A galactose analogue that is an UDP-glucose ceramide glucosyltransferase (UGCG/GCS) inhibitor (IC50=41.4 uM).

A galactose analogue that is an UDP-glucose ceramide glucosyltransferase (UGCG/GCS) inhibitor (IC50=41.4 uM); prevents glucosylceramide biosynthesis both in vitro and in mouse models of lysosome storage disorders, without affecting α-glucosidase I and II or β-glucocerebrosidase (IC50>1 mM); shows potential as substrate reduction therapy for glycolipid storage disorders such as Gaucher disease and Fabry disease.Other Indication Phase 1 Clinical

N-Butyldeoxygalactonojirimycin;ACT-434964;OGT-923

Others

Other Targets

Other Targets

Other Indications

Other Disease

141206-42-0

219.28

C10H21NO4

>98% (HPLC)

——

O[C@H]1[C@@H](CO)N(CCCC)C[C@H](O)[C@H]1O

(2R,3S,4R,5S)-1-butyl-2-(hydroxymethyl)piperidine-3,4,5-triol

(-20℃)

With Ice Pack

≥ 2 years